Buyer's Guide

Contact | Print version | PDF version | Recommend company

Portrait
Jerini is a pharmaceutical company based in Berlin, Germany, focusing on the discovery, development, and commercialization of novel peptide-based drugs. The company pursues disease indications that have limited or no treatment options and has built a drug pipeline composed of its own programs, along with those developed in collaboration with established partners. Having received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) for Icatibant in the acute treatment of HAE, Jerini’s sales and marketing teams are ready to launch the product in the third quarter of 2008. Icatibant is a first-in-class compound and will be the first product to be approved for HAE treatment in all European countries. Based on its P2D platform, Jerini has established several in-house development programs addressing indications within the therapeutic areas of ophthalmology, oncology, and inflammatory disease.

Industrial Sectors

Custom Manufacturing

Medicine/Pharmacy

Biotechnical Products